Gilead Sciences (GILD) Jumped 4% While Regeneron (REGN) Held Steady Following Improved Quarterly Performances
Gilead Sciences, Inc. (GILD) increased to $68.46, seeing a rise of +4 percent on Friday. In the fourth quarter, GILD announced revenue of $1.9 billion for its Covid-19 treatment. An increasing 2021 financial year and high Remdesivir revenues are anticipated by the company. With this antiviral drug used to regulate Covid-19, sales for the fourth […]
